ALIBABA-GROUP
Alibaba A.I. Labs, an AI research division of Alibaba Group, today announced at CES Asia partnerships with auto brands, including Audi, Renault and Honda to drive a smart mobility initiative in China.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190610005833/en/
Tmall Genie Auto, an Artificial Intelligence solution developed by Alibaba A.I. Labs, will be integrated into the automakers’ specific internet cars in China.
Owners of the three auto brands’ specific-model vehicles equipped with Tmall Genie Auto will have access to a wide variety of voice-controlled information and services in the near future; these include identifying nearby attractions and restaurants, booking movie tickets, ordering to-go boxes, checking the status of package deliveries, reading children’s books and ordering items on Alibaba’s retail platform.
In addition, car owners with a Tmall Genie-compatible device at home would be able to monitor and control their smart-home devices from their cars in the near future, performing daily tasks such as running a status check on temperature and light, or turning on the heater and air conditioning at home.
“By providing AI technologies, including speech-recognition and Natural Language Processing, Tmall Genie Auto enables car users to access an extensive in-car infotainment portfolio by tapping into Alibaba’s rich content and service ecosystem,” said Miffy Chen, General Manager at Alibaba A.I. Labs . “We are thrilled to partner with global distinguished auto brands such as Audi, Renault and Honda. Together, we can greatly enhance our in-car services and make driving experience more intelligent and interconnected.”
“We aim to extend in-car voice assistant services according to the demands and needs of our Chinese customers,” said H.W. Vassen, Senior Director of Digitalization and NEV Development at Audi China . “To do so, one of our next steps is to intensity the cooperation with Alibaba Tmall Genie.”
Guillaume SICARD, Vice President of Sales and Marketing, Region China, Groupe Renault , commented: “The launch of the Renault City K-ZE Tmall Genie Edition allows consumers to experience a deeper connection between scenarios in their lives at home and their lives on the go. It is also a manifesto that DRAC and Tmall will continue to maintain profound cooperation on areas such as brand marketing, potential customer mining and sales network enablement, in order to achieve new breakthroughs.”
Hasegawa Yusuke, the Executive Vice President of Honda Motor (China) Investment Co., Ltd , said: “The world’s mobility industries are currently undergoing a major transformation. Our mobility and daily lives will finally enter into the era of Internet for Everything, Honda has been actively embracing the trend of electrification and ICVs, and accelerating the advancement of the third-generation Honda CONNECT system which includes the Smart AI function. We look forward to working with Alibaba A.I. Labs on creative initiatives by leveraging the AI technology and Alibaba’s diverse ecosystem services.”
During CES Asia, Alibaba’s B2C marketplace Tmall also announced its tie-up with Renault to roll out an electric car featuring Tmall’s iconic cat logo on the vehicle’s exterior design. The Renault City K-ZE genie edition, also integrated with Tmall Genie Auto, will be on sale in China later this year.
Tmall Genie is the bestselling smart speaker in China. Today it can control over 100 million devices from over 600 smart appliance brands, offering its Internet of Things ecosystem capabilities to various sectors and user environments from home, car, hotels to nursing homes.
Alibaba A.I. Labs spearheads consumer AI product development at Alibaba Group. Since the launch of Tmall Genie Auto solution last April, Alibaba A.I. Labs has also partnered with auto brands including BMW and Volvo Cars to provide intelligent and connected mobility experiences for consumers in China.
About Alibaba A.I. Labs
Alibaba A.I. Labs is dedicated to exploring the next-generation human-and-computer interaction and turning novel user experience into reality. The in-house R&D department focuses on the development of innovative AI applications across Alibaba’s commerce ecosystem and provides AI solutions to Alibaba’s clients and partners. With a world-class research team, Alibaba A.I. Labs focuses on both theoretical research and product commercialization in various areas, including speech recognition, natural language processing, voice print identification, deep learning, and computer vision. The Labs also focuses on developing AI products for consumers, including Tmall Genie, the first voice- controlled smart home assistant developed by the Labs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190610005833/en/
Contact:
Crystal Liu Alibaba Group +86 18578497650/+852 6378 5626 Crystal.liu@alibaba-inc.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom